文献速递流行病学与生物统计真实世界研究与卫生经济

估算美国FDA自愿性钠配方改革对健康与经济的影响:微观模拟成本效果分析

Estimating the health and economic effects of the proposed US Food and Drug Administration voluntary sodium reformulation: Microsimulation cost-effectiveness analysis.
PubMed 文献 · PLoS Med · 2018-04-10

该研究采用微观模拟模型评估FDA自愿性钠减量目标在2017至2036年间的健康与经济影响,设置三种依从性场景。

要点

  • 所有场景在2021年前具成本效果,2031年前可节省成本。
  • 模型仅评估血压介导的疾病,未涵盖其他健康获益。

核心结论

  • 实施并达成FDA钠配方改革目标可产生显著健康获益和净成本节省。

研究设计与样本

  • 采用美国IMPACT食品政策模型对接近现实的合成人群进行微观模拟,评估2017至2036年三种钠减量场景。
  • 数据输入来自国家健康与营养调查(NHANES)及高质量荟萃分析。

主要发现

  • 所有场景在2021年前具有超过80%概率具成本效果(增量成本/QALY < 10万美元),并在2031年前变为成本节省。

关键数值与推荐

  • 成本效果阈值:增量成本/QALY < 10万美元。

临床怎么用

  • 支持FDA自愿性钠减量政策作为改善心血管健康和节约医疗成本的策略。

局限性

  • 仅评估血压介导的疾病,未考虑减钠对其他健康负担(如胃癌)的潜在益处。
  • 模型效应估计基于干预性和前瞻性观察研究,可能受偏倚和混杂影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium consumption is a modifiable risk factor for higher blood pressure (BP) and cardiovascular disease (CVD). The US Food and Drug Administration (FDA) has proposed voluntary sodium reduction goals targeting processed and commercially prepared foods. We aimed to quantify the potential health and economic impact of this policy. METHODS AND FINDINGS: We used a microsimulation approach of a close-to-reality synthetic population (US IMPACT Food Policy Model) to estimate CVD deaths and cases prevented or postponed, quality-adjusted life years (QALYs), and cost-effectiveness from 2017 to 2036 of 3 scenarios: (1) optimal, 100% compliance with 10-year reformulation targets; (2) modest, 50% compliance with 10-year reformulation targets; and (3) pessimistic, 100% compliance with 2-year reformulation targets, but with no further progress. We used the National Health and Nutrition Examination Survey and high-quality meta-analyses to inform model inputs. Costs included government costs to administer and monitor the policy, industry reformulation costs, and CVD-related healthcare, productivity, and informal care costs. Between 2017 and 2036, the optimal reformulation scenario achieving the FDA sodium reduction targets could prevent approximately 450,000 CVD cases (95% uncertainty interval: 240,000 to 740,000), gain approximately 2.1 million discounted QALYs (1.7 million to 2.4 million), and produce discounted cost savings (health savings minus policy costs) of approximately $41 billion ($14 billion to $81 billion). In the modest and pessimistic scenarios, health gains would be 1.1 million and 0.7 million QALYS, with savings of $19 billion and $12 billion, respectively. All the scenarios were estimated with more than 80% probability to be cost-effective (incremental cost/QALY < $100,000) by 2021 and to become cost-saving by 2031. Limitations include evaluating only diseases mediated through BP, while decreasing sodium consumption could have beneficial effects upon other health burdens such as gastric cancer. Further, the effect estimates in the model are based on interventional and prospective observational studies. They are therefore subject to biases and confounding that may have influenced also our model estimates. CONCLUSIONS: Implementing and achieving the FDA sodium reformulation targets could generate substantial health gains and net cost savings.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Pearson-Stuttard J, Kypridemos C, Collins B, et al. Estimating the health and economic effects of the proposed US Food and Drug Administration voluntary sodium reformulation: Microsimulation cost-effectiveness analysis. PLoS Med. 2018. PMID: 29634725. doi:10.1371/journal.pmed.1002551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。